Aliskiren Study of Safety and Efficacy in Senior Hypertensives

Exclusion Criteria

• •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
• •Severe hypertension (MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg) at Visit 1, Visit 2, Visit 201 or Visit 3 or during patient self measured blood pressure (SMBP) monitoring in the pre-randomization period confirmed by office measurement.
• •Current treatment with any blocker of the renin angiotensin aldosterone system (RAAS) (aliskiren, ACE inhibitor, angiotensin receptor blocker or an aldosterone antagonist) and unable to discontinue this therapy.
• •Concurrent use of any anti-hypertensive medications except a stable dose of 3 months prior to Visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy (e.g., tamsulosin \[Flomax®\] for benign prostatic hypertrophy), beta blockers for angina, or beta blocker ophthalmic preparations.